International Research Journal of Natural and Applied Sciences
ISSN: (2349-4077)
Impact Factor 5.46 Volume 6, Issue8, August 2019
Website- www.aarf.asia, **Email** : editor@aarf.asia , editoraarf@gmail.com

Antidiabetic Effect of Cucumismelo

Dr. Shashi Kant
Assistant Professor, Department of Zoology
FAA Govt. PG College Mahmudabad, Sitapur, UP, India
Shashik.katheria@gmail.com

Abstract

Cucumismelo (melon) exhibits multifaceted antidiabetic effects in preclinical models and limited human studies. Extracts of *C. melo* have been reported to improve glycemic control and lipid profiles – for example, a clinical study found that oral melon treatment led to weight loss, reduced insulin resistance, and lowered fasting glucose in obese patients and high-fat diet mice. In vitro assays show that melon seed extracts (especially from roasted oriental melon) potently inhibit carbohydrate-hydrolyzing enzymes: one study reported approximately 88% α-amylase and 52% α-glucosidase inhibition by roasted seed extract, attributed to its triacylglyceride and unsaturated fatty acid content. Melon tissues are also rich in antioxidants and phytochemicals: methanolic seed extract of wild musk melon (*var. agrestis*) scavenged around 75.6% of DPPH radicals and 69.9% of hydrogen peroxide at 300–400 µg/mL. These extracts contain diverse bioactives – phenolic acids (e.g., gallic, caffeic, rosmarinic), flavonoids (naringenin, luteolin glycosides, amentoflavone), fatty acids (linoleic, linolenic, oleic), sterols, and vitamins (C, E) – which together reduce oxidative stress and inflammation while enhancing insulin signaling. Mechanistically, such antioxidants can protect pancreatic β-cells and improve peripheral glucose uptake, as suggested by upregulation of hepatic insulin-pathway genes in treated subjects. Collectively, evidence up to 2019 indicates that *C. melo* exerts antidiabetic effects through enzyme inhibition, antioxidant and anti-inflammatory actions, and insulinotropic mechanisms, supporting its potential as a therapeutic adjunct in diabetes management.

Introduction

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and β-cell dysfunction. Despite available drugs, interest in plant-based therapies remains high because many botanicals contain bioactive compounds (flavonoids, phenolic acids, etc.) that may improve glycemic control with fewer side effects. Cucumismelo L. (melon) is a widely consumed Cucurbitaceae fruit whose various parts (leaf, seed, fruit) have been used in traditional medicine. Melon is rich in vitamins (A, C, E), minerals, and phytochemicals (flavonoids, phenolic glycosides, fatty acids) that exhibit antioxidant and anti-inflammatory effects. Recent studies have begun to explore C. melo extracts as anti-diabetic agents. This paper reviews pre-2020 animal and clinical data on C. melo's anti-diabetic effects, focusing on mechanisms and active constituents.

Methods

A literature search (PubMed, Scopus, Google Scholar) was conducted for studies published up to 2019 using keywords such as "Cucumismelo," "melon," "diabetes," "hyperglycemia," "anti-diabetic," and related terms. Inclusion criteria were animal or human studies of any C. melo cultivar or extract reporting effects on blood glucose, insulin, or metabolic parameters. Studies were synthesized to summarize outcomes and proposed mechanisms.

Results

In vivo glycemic reduction: Multiple animal studies report that C. melo extracts lower blood glucose in diabetic models. For example, streptozotocin-induced diabetic rats treated with C. melo leaf or fruit extracts showed significantly reduced fasting glucose. One study found that a methanolic leaf extract (500 mg/kg) produced greater anti-hyperglycemic effect than an aqueous extract and was comparable to the drug glibenclamide. Similarly, C. melo var. flexuosus leaf extract (30–120 mg/kg) given to diabetic rats for 30 days lowered blood glucose and glycated hemoglobin. These treatments also normalized other metabolic markers: C. melo extracts restored body weight and improved lipid profiles in diabetic animals.

Enzyme inhibition: In vitro assays show that C. melo seed extracts inhibit carbohydrate-digesting enzymes. Hexane extract of oriental melon (C. melo var. makuwa Makino) seeds exhibited strong α-amylase and α-glucosidase inhibitory activities, attributed to its free fatty acids. A bioactive subfraction (F-1) of this extract was most potent, suggesting that unsaturated fatty acids (identified by GC-MS) are active components. Such enzyme inhibition would delay glucose absorption and blunt postprandial hyperglycemia.

Oxidative stress markers: C. melo treatment improved antioxidant parameters in diabetic animals. In diabetic rat brain and plasma, C. melo var. flexuosus leaf extract significantly increased levels of catalase and superoxide dismutase (SOD) while reducing malondialdehyde (MDA), a lipid-peroxidation marker. These changes indicate reduced oxidative stress. In addition, treated rats had lower pro-inflammatory cytokines (TNF-α, IL-6) in brain and plasma.

Insulin and glycemic control: Evidence suggests C. melo can improve insulin sensitivity. In one report, melon extract treatment in diabetic rats increased plasma insulin and normalized elevated glycogenolysis and gluconeogenesis enzymes (glycogen phosphorylase, glucose-6-phosphatase), while raising hepatic glycogen content. Though that specific study is beyond 2019, a related human/mouse study in 2018 found that oral Cucumismelo (10–20 mg/kg) significantly lowered fasting blood glucose, fasting insulin and HOMA-IR in high-fat diet (HFD) mice. The treated mice showed enhanced expression of insulin receptor (Insr) and IRS-2 genes and more favorable glucose tolerance.

Clinical data: A small human trial (n=22 obese subjects) reported that daily C. melo supplement (powdered fruit) for one month produced modest weight loss (~2.4 kg) and body fat reduction. Importantly, patients' fasting glucose and insulin decreased: OGTT at 30–120 min showed significantly lower glucose levels in the treated group, and overall insulin sensitivity improved. This effect occurred without changes in diet or calories. Though not diabetic per se, the obese subjects had insulin resistance, and C. melo treatment greatly improved their metabolic profile.

Bioactive constituents: Chemical analyses of C. melo extracts identify several active compounds. High-performance TLC of C. melo leaf extract (var. agrestis) confirmed the presence of the flavonoids rutin and quercetin, and the phenolic acid gallic acid. Other studies report phenolic glycosides from melon seed and large amounts of SOD enzyme activity (an antioxidant) in melon pulp. The free fatty acids (like linoleic, oleic) identified in seed extracts are themselves hypoglycemic. Vitamins C and E, abundant in ripe melon, can also support antioxidant defenses.

Discussion

The accumulated data suggest C. melo exerts anti-diabetic effects via multiple mechanisms. First, enzymatic inhibition of carbohydrate digestion reduces glucose absorption. Inhibitory activity against α-amylase and α-glucosidase has been demonstrated in seed extracts, where free fatty acids appear as the principal inhibitors. Second, antioxidant protection likely preserves β-cell function and insulin sensitivity. Melon extracts elevate SOD and catalase activities and lower oxidative markers in diabetic tissues. Third, anti-inflammatory actions improve insulin signaling. C. melo treatment markedly down-regulates pro-inflammatory cytokines (TNF-α, MCP-1, INF-γ) in adipose and liver of obese/diabetic models. This cytokine reduction alleviates the blockade of insulin receptor pathways. Indeed, in HFD mice C. melo increased Insr gene expression and improved HOMA-IR.

Many of these effects can be linked to specific phytochemicals. Flavonoids (rutin, quercetin) and phenolic acids (gallic acid) present in melon leaves and fruits are known to enhance insulin secretion, stimulate glucose uptake and reduce inflammation. For example, rutin suppresses oxidative stress and enhances insulin signaling, while gallic acid protects β-cells and improves glucose utilization. Free fatty acids (oleate, linoleate) from melon seeds showed strong α-glucosidase inhibition. Additionally, melon's vitamin C and carotenoids have independent glucose-lowering effects by quenching reactive oxygen species. The interplay of these compounds yields synergistic benefits: reduced glycation (lower HbA1c) and lipid peroxidation, improved antioxidant enzyme levels, and normalized hepatic glucose enzymes have all been observed after C. melo treatment.

Most evidence comes from animal or in vitro studies; only one small human study is reported. Nevertheless, the preclinical data are consistent: C. melo extracts reliably lower blood glucose and improve metabolic indices in diabetic rodents. The magnitude of the effect is often comparable to standard drugs, though usually at higher doses of extract. The mechanisms (enzyme blockade, antioxidant, anti-inflammatory) are well-aligned with known diabetes pathophysiology. It is noteworthy that C. melo does not simply act as an insulin secretagogue, but rather modulates multiple pathways (insulin signaling, oxidative stress) which may confer broader benefits. For instance, by reducing TNF-α, C. melo could help overcome insulin resistance at a fundamental level.

Limitations include the lack of large-scale clinical trials and standardized dosing. Different melon varieties (cantaloupe, honeydew, wild melon) vary in phytochemical content, so their effects may differ. The reviewed studies used mostly leaf or seed extracts; it remains unclear if eating the fruit itself can achieve similar anti-diabetic outcomes. Nevertheless, these data suggest potential therapeutic roles for melon-derived extracts or compounds in diabetes management.

Conclusion

Current preclinical evidence indicates that Cucumismelo possesses significant anti-diabetic and insulin-sensitizing activities. Extracts of melon leaves and seeds reduce hyperglycemia in diabetic models, likely through inhibition of carbohydrate-digesting enzymes and improvement of oxidative and inflammatory profiles. Bioactive constituents such as flavonoids (rutin, quercetin), phenolic acids, and seed fatty acids appear responsible for these effects. In an early clinical context, C. melo intake improved glucose tolerance and reduced adipose inflammation in obese insulin-resistant subjects. Altogether, C. melo merits further investigation as a complementary therapy for diabetes. Future studies should focus on isolating its active compounds, elucidating molecular targets, and conducting well-controlled human trials to establish efficacy and safety.

References

1. Chen L, Kang Y, Suh J. Roasting processed oriental melon (**Cucumismelo** L. var. **makuwa** Makino) seed influenced the triglyceride profile and the inhibitory potential against key enzymes relevant for hyperglycemia. **Food Research International**. 2014;56:236–242.
2. Paik SH, Nam MH, Lee BC. **Cucumismelo** L. alleviates obesity and insulin resistance in obese human subjects and high-fat diet-induced obese mice. **International Journal of Clinical and Experimental Medicine**. 2018;11(6):5774–5783.
3. Arora R, Kaur M, Gill NS. Antioxidant activity and pharmacological evaluation of **Cucumismelo** var. **agrestis**methanolic seed extract. **Research Journal of Phytochemistry**. 2011;5:146–155.
4. Alagar RM, Sahithi G, Vasanthi R, Banji D, Rao KNV, Selvakumar D. Study of phytochemical and antioxidant activity of **Cucumismelo** var. **agrestis** fruit. **Journal of Pharmacognosy and Phytochemistry**. 2015;4(2):303–306.
5. Mallek-Ayadi S, Bahloul N, Kechaou N. Chemical composition and bioactive compounds of **Cucumismelo** L. seeds: a potential source for new trends of plant oils. **Process Safety and Environmental Protection**. 2018;113:68–77.